The results of a phase 2 trial indicate that a new drug to treat type 2 diabetes shows promise in improving the blood sugar of patients without increasing risk of low blood sugar, or hypoglycemia.
Type 2 diabetes is the one often referred to as “lifestyle-related” diabetes, and is linked with obesity and often other habits. More than 90% of diabetes in general are type 2, with a far smaller portion being type 1 or what has been called juvenile diabetes. According to US News and World Report, type 2 diabetes often “involves a gradual decline in how insulin responds to changes in blood sugar,” or glucose, and the medication used in the trial could be more efficient at treating the condition specifically.
The new drug, TAK-875, responds to changes in blood sugar rather than affecting insulin when blood sugar is well-regulated, slicing the risk of hypoglycemia in type 2 diabetics. The study involved more than 400 patients whom the study identified as “not getting adequate blood sugar control through diet, exercise or treatment with the first-line diabetes drug metformin.” 303 patients were given TAK-875, 61 received a placebo and the remaining patients were treated with another diabetes drug, Amaryl.
Dr. Minisha Sood is an endocrinologist at Lenox Hill Hospital in New York City, and Sood commented:
“…given the rising global incidence of type 2 diabetes, the medical community is eagerly awaiting the development of novel agents to add to our existing armamentarium of anti-diabetic agents… though this study includes a small sample size followed for a short period of time, the results are promising in that TAK-875 appears to be effective for glycemic [blood sugar] control without significant risk for hypoglycemia or weight gain.”
Sood noted that further study is needed, particularly when patients with heart disease are concerned.